These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19109382)

  • 1. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.
    Lobigs M; Larena M; Alsharifi M; Lee E; Pavy M
    J Virol; 2009 Mar; 83(6):2436-45. PubMed ID: 19109382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.
    Lobigs M; Pavy M; Hall RA; Lobigs P; Cooper P; Komiya T; Toriniwa H; Petrovsky N
    J Gen Virol; 2010 Jun; 91(Pt 6):1407-17. PubMed ID: 20130134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunisation with gamma globulin to murray valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against australian encephalitis: evaluation in a mouse model.
    Broom AK; Wallace MJ; Mackenzie JS; Smith DW; Hall RA
    J Med Virol; 2000 Jun; 61(2):259-65. PubMed ID: 10797383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals.
    Bielefeldt-Ohmann H; Prow NA; Wang W; Tan CS; Coyle M; Douma A; Hobson-Peters J; Kidd L; Hall RA; Petrovsky N
    Vet Res; 2014 Dec; 45(1):130. PubMed ID: 25516480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
    Beasley DW; Li L; Suderman MT; Guirakhoo F; Trent DW; Monath TP; Shope RE; Barrett AD
    Vaccine; 2004 Sep; 22(27-28):3722-6. PubMed ID: 15315852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.
    Petrovsky N; Larena M; Siddharthan V; Prow NA; Hall RA; Lobigs M; Morrey J
    J Virol; 2013 Sep; 87(18):10324-33. PubMed ID: 23864620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice.
    Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
    Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
    J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of swine by potent neutralizing anti-Japanese encephalitis virus monoclonal antibodies derived from vaccination.
    Young CL; Lyons AC; Hsu WW; Vanlandingham DL; Park SL; Bilyeu AN; Ayers VB; Hettenbach SM; Zelenka AM; Cool KR; Peterson GJ; Higgs S; Huang YS
    Antiviral Res; 2020 Feb; 174():104675. PubMed ID: 31825852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
    Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F
    Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
    Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine.
    Wang R; Zhen Z; Turtle L; Hou B; Li Y; Wu N; Gao N; Fan D; Chen H; An J
    Appl Microbiol Biotechnol; 2020 Aug; 104(15):6779-6789. PubMed ID: 32556415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cross-protection against two wild-type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine.
    Wu CJ; Huang HW; Tao MH
    Vaccine; 2003 Sep; 21(25-26):3938-45. PubMed ID: 12922129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.
    Hegde NR; Gore MM
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-18. PubMed ID: 28301270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.